{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T18:03:31Z","timestamp":1793556211662,"version":"4.5.0"},"reference-count":106,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Gastric cancer is one of the most common malignant tumors of the digestive system, with persistently high global morbidity and mortality rates. The multi-level heterogeneity of the gastric cancer tumor immune microenvironment (TIME) is closely associated with treatment efficacy and prognosis. This heterogeneity is reflected not only in the types and functions of various cells within the microenvironment but also in multiple aspects such as molecular profiles, metabolic pathways, and the spatial distribution of tumor cells. Currently, the interaction between gastric cancer and its microenvironment, as well as the resulting immune evasion, has become a research hotspot. This article reviews the role of cellular heterogeneity and metabolic reprogramming in the gastric cancer Tumor Immune Microenvironment (TIME) in reshaping the immune microenvironment, and summarizes traditional therapies alongside existing and potential microenvironment-modulating treatment strategies.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1623588","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T05:34:32Z","timestamp":1756964072000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Multimodal therapeutic strategies against gastric cancer: from conventional treatments to tumor microenvironment targeting"],"prefix":"10.3389","volume":"16","author":[{"given":"Xi","family":"Yuan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changxian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixuan","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuanzhi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anying","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2022.0182","article-title":"Surgical management of gastric cancer: A review","volume":"157","author":"Li","year":"2022","journal-title":"JAMA Surg"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2025.0022","article-title":"Gastric cancer, version 2.2025, nccn clinical practice guidelines in oncology","volume":"23","author":"Ajani","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12516","article-title":"The chinese society of clinical oncology (Csco): clinical guidelines for the diagnosis and treatment of gastric cancer, 2023","volume":"44","author":"Wang","year":"2024","journal-title":"Cancer Commun (Lond)"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21689","article-title":"Radiation therapy-associated toxicity: etiology, management, and prevention","volume":"71","author":"Wang","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B6","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13045-023-01451-3","article-title":"Gastric cancer treatment: recent progress and future perspectives","volume":"16","author":"Guan","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2024.101080","article-title":"Circumventing drug resistance in gastric cancer: A spatial multi-omics exploration of chemo and immuno-therapeutic response dynamics","volume":"74","author":"Che","year":"2024","journal-title":"Drug Resist Update"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3394","article-title":"Microenvironmental regulation of tumor progression and metastasis","volume":"19","author":"Quail","year":"2013","journal-title":"Nat Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (Time) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31288-5","article-title":"Gastric cancer","volume":"396","author":"Smyth","year":"2020","journal-title":"Lancet"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2022.07.002","article-title":"Inflammation: the incubator of the tumor microenvironment","volume":"8","author":"Denk","year":"2022","journal-title":"Trends Cancer"},{"key":"B12","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s10020-025-01075-y","article-title":"Targeted therapy and immunotherapy for gastric cancer: rational strategies, novel advancements, challenges, and future perspectives","volume":"31","author":"Luo","year":"2025","journal-title":"Mol Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21657","article-title":"Current treatment and recent progress in gastric cancer","volume":"71","author":"Joshi","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-022-01267-2","article-title":"The complex role of tumor-infiltrating macrophages","volume":"23","author":"Christofides","year":"2022","journal-title":"Nat Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2020.12.014","article-title":"Extracellular vesicle activities regulating macrophage- and tissue-mediated injury and repair responses","volume":"11","author":"Hu","year":"2021","journal-title":"Acta Pharm Sin B"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1386","article-title":"Tumour-associated macrophages in gastric cancer: from function and mechanism to application","volume":"13","author":"Li","year":"2023","journal-title":"Clin Transl Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"3928","DOI":"10.1038\/s41467-019-11788-4","article-title":"Macrophage spatial heterogeneity in gastric cancer defined by multiplex immunohistochemistry","volume":"10","author":"Huang","year":"2019","journal-title":"Nat Commun"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202309298","article-title":"M2 tumor-associated macrophages-derived exosomal malat1 promotes glycolysis and gastric cancer progression","volume":"11","author":"Wang","year":"2024","journal-title":"Adv Sci (Weinh)"},{"key":"B19","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1007\/s10120-024-01517-2","article-title":"Tmem205 induces tam\/M2 polarization to promote cisplatin resistance in gastric cancer","volume":"27","author":"Fu","year":"2024","journal-title":"Gastric Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-024-03269-4","article-title":"Gastric cancer-derived exosomal let-7 g-5p mediated by serpine1 promotes macrophage M2 polarization and gastric cancer progression","volume":"44","author":"Ye","year":"2025","journal-title":"J Exp Clin Cancer Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/nri2506","article-title":"Myeloid-derived suppressor cells as regulators of the immune system","volume":"9","author":"Gabrilovich","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12156","article-title":"The role of myeloid-derived suppressor cells in gastrointestinal cancer","volume":"41","author":"Cui","year":"2021","journal-title":"Cancer Commun (Lond)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00846-y","article-title":"Myeloid-derived suppressor cells in cancer and cancer therapy","volume":"21","author":"Lasser","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2019-318817","article-title":"Mir130b from schlafen4(+) mdscs stimulates epithelial proliferation and correlates with preneoplastic changes prior to gastric cancer","volume":"69","author":"Ding","year":"2020","journal-title":"Gut"},{"key":"B25","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1053\/j.gastro.2022.04.031","article-title":"Toll-like receptor 9 pathway mediates schlafen(+)-mdsc polarization during helicobacter-induced gastric metaplasias","volume":"163","author":"Ding","year":"2022","journal-title":"Gastroenterology"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.215598","article-title":"Pmn-mdscs accumulation induced by cxcl1 promotes cd8(+) T cells exhaustion in gastric cancer","volume":"532","author":"Zhou","year":"2022","journal-title":"Cancer Lett"},{"key":"B27","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1038\/s41571-021-00546-5","article-title":"Clinical and therapeutic relevance of cancer-associated fibroblasts","volume":"18","author":"Chen","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.02.015","article-title":"Activated fibroblasts in cancer: perspectives and challenges","volume":"41","author":"Caligiuri","year":"2023","journal-title":"Cancer Cell"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.7150\/thno.60540","article-title":"Single-cell rna sequencing reveals a pro-invasive cancer-associated fibroblast subgroup associated with poor clinical outcomes in patients with gastric cancer","volume":"12","author":"Li","year":"2022","journal-title":"Theranostics"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217422","article-title":"M6a demethylation of nnmt in cafs promotes gastric cancer progression by enhancing macrophage M2 polarization","volume":"611","author":"Mak","year":"2024","journal-title":"Cancer Lett"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1173-8","article-title":"Proteomics reveals nnmt as a master metabolic regulator of cancer-associated fibroblasts","volume":"569","author":"Eckert","year":"2019","journal-title":"Nature"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1038\/s41467-025-57465-7","article-title":"Antigen-presenting cancer associated fibroblasts enhance antitumor immunity and predict immunotherapy response","volume":"16","author":"Song","year":"2025","journal-title":"Nat Commun"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/ni904","article-title":"Foxp3 programs the development and function of cd4+Cd25+ Regulatory T cells","volume":"4","author":"Fontenot","year":"2003","journal-title":"Nat Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00870-6","article-title":"Regulatory T cell-mediated immunosuppression orchestrated by cancer: towards an immuno-genomic paradigm for precision medicine","volume":"21","author":"Kumagai","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2025.01.001","article-title":"Ccr8: A promising therapeutic target against tumor-infiltrating regulatory T cells","volume":"46","author":"Wen","year":"2025","journal-title":"Trends Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33873","article-title":"The effects of tnf-\u03b1\/tnfr2 in regulatory T cells on the microenvironment and progression of gastric cancer","volume":"150","author":"Qu","year":"2021","journal-title":"Int J Cancer"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jare.2023.04.013","article-title":"Tumor-infiltrating mast cells stimulate icos(+) regulatory T cells through an il-33 and il-2 axis to promote gastric cancer progression","volume":"57","author":"Lv","year":"2024","journal-title":"J Adv Res"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/s44321-024-00120-3","article-title":"Immunotherapies targeting the oncogenic fusion gene cldn18-arhgap in gastric cancer","volume":"16","author":"Wang","year":"2024","journal-title":"EMBO Mol Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.2801","article-title":"Method of the year 2013","volume":"11","year":"2014","journal-title":"Nat Methods"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-19-3231","article-title":"Single-cell genomic characterization reveals the cellular reprogramming of the gastric tumor microenvironment","volume":"26","author":"Sathe","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1093\/nsr\/nwad094","article-title":"Integrative single-cell multiomics analyses dissect molecular signatures of intratumoral heterogeneities and differentiation states of human gastric cancer","volume":"10","author":"Bian","year":"2023","journal-title":"Natl Sci Rev"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1490","article-title":"Single-cell profiling reveals tumour cell heterogeneity accompanying a pre-malignant and immunosuppressive microenvironment in gastric adenocarcinoma","volume":"13","author":"Ge","year":"2023","journal-title":"Clin Transl Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1125-8","article-title":"Single-cell dissection of intratumoral heterogeneity and lineage diversity in metastatic gastric adenocarcinoma","volume":"27","author":"Wang","year":"2021","journal-title":"Nat Med"},{"key":"B44","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/s41576-019-0129-z","article-title":"Spatial transcriptomics coming of age","volume":"20","author":"Burgess","year":"2019","journal-title":"Nat Rev Genet"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/s41592-020-01042-x","article-title":"Method of the year 2020: spatially resolved transcriptomics","volume":"18","year":"2021","journal-title":"Nat Methods"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-021-01075-3","article-title":"Super-resolved spatial transcriptomics by deep data fusion","volume":"40","author":"Bergenstr\u00e5hle","year":"2022","journal-title":"Nat Biotechnol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-023-02019-9","article-title":"Inferring super-resolution tissue architecture by integrating spatial transcriptomics with histology","volume":"42","author":"Zhang","year":"2024","journal-title":"Nat Biotechnol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1053\/j.gastro.2024.08.007","article-title":"Spatially resolved niche and tumor microenvironmental alterations in gastric cancer peritoneal metastases","volume":"167","author":"Zhao","year":"2024","journal-title":"Gastroenterology"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2024.06.026","article-title":"100 years of the warburg effect: A cancer metabolism endeavor","volume":"187","author":"Fendt","year":"2024","journal-title":"Cell"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1126\/science.1160809","article-title":"Understanding the warburg effect: the metabolic requirements of cell proliferation","volume":"324","author":"Vander Heiden","year":"2009","journal-title":"Science"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2123231119","article-title":"Dual roles of \u03b2-arrestin 1 in mediating cell metabolism and proliferation in gastric cancer","volume":"119","author":"Yu","year":"2022","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B52","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1186\/s12935-023-03162-8","article-title":"Glucose transporter 3 (Glut3) promotes lactylation modifications by regulating lactate dehydrogenase a (Ldha) in gastric cancer","volume":"23","author":"Yang","year":"2023","journal-title":"Cancer Cell Int"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-07620-9","article-title":"Nbs1 lactylation is required for efficient DNA repair and chemotherapy resistance","volume":"631","author":"Chen","year":"2024","journal-title":"Nature"},{"key":"B54","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.ccell.2022.01.001","article-title":"Lactic acid promotes pd-1 expression in regulatory T cells in highly glycolytic tumor microenvironments","volume":"40","author":"Kumagai","year":"2022","journal-title":"Cancer Cell"},{"key":"B55","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.cmet.2019.11.010","article-title":"Greasing the wheels of the cancer machine: the role of lipid metabolism in cancer","volume":"31","author":"Snaebjornsson","year":"2020","journal-title":"Cell Metab"},{"key":"B56","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.immuni.2020.06.016","article-title":"An oncogenic alteration creates a microenvironment that promotes tumor progression by conferring a metabolic advantage to regulatory T cells","volume":"53","author":"Kumagai","year":"2020","journal-title":"Immunity"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12583","article-title":"Leptin-mediated suppression of lipoprotein lipase cleavage enhances lipid uptake and facilitates lymph node metastasis in gastric cancer","volume":"44","author":"Xiao","year":"2024","journal-title":"Cancer Commun (Lond)"},{"key":"B58","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1053\/j.gastro.2024.01.027","article-title":"Oncogenic fatty acid metabolism rewires energy supply chain in gastric carcinogenesis","volume":"166","author":"Won","year":"2024","journal-title":"Gastroenterology"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2024.2307542","article-title":"Gut microbiota modulate cd8(+) T cell immunity in gastric cancer through butyrate\/gpr109a\/hopx","volume":"16","author":"Yu","year":"2024","journal-title":"Gut Microbes"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-023-00557-7","article-title":"Nucleotide metabolism: A pan-cancer metabolic dependency","volume":"23","author":"Mullen","year":"2023","journal-title":"Nat Rev Cancer"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/j.chom.2023.06.016","article-title":"A single-nucleotide polymorphism in helicobacter pylori promotes gastric cancer development","volume":"31","author":"Sharafutdinov","year":"2023","journal-title":"Cell Host Microbe"},{"key":"B62","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1038\/s41419-024-07052-3","article-title":"The nrf2-carm1 axis links glucose sensing to transcriptional and epigenetic regulation of the pentose phosphate pathway in gastric cancer","volume":"15","author":"Ping","year":"2024","journal-title":"Cell Death Dis"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.215837","article-title":"De novo pyrimidine synthesis fuels glycolysis and confers chemoresistance in gastric cancer","volume":"549","author":"He","year":"2022","journal-title":"Cancer Lett"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12459","article-title":"Glutamine metabolic microenvironment drives M2 macrophage polarization to mediate trastuzumab resistance in her2-positive gastric cancer","volume":"43","author":"Hu","year":"2023","journal-title":"Cancer Commun (Lond)"},{"key":"B65","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1038\/s41392-020-00359-5","article-title":"Exosome-mediated metabolic reprogramming: the emerging role in tumor microenvironment remodeling and its influence on cancer progression","volume":"5","author":"Yang","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01168-8","article-title":"Caf secreted mir-522 suppresses ferroptosis and promotes acquired chemo-resistance in gastric cancer","volume":"19","author":"Zhang","year":"2020","journal-title":"Mol Cancer"},{"key":"B67","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12943-024-01966-4","article-title":"Exosome circatp8a1 induces macrophage M2 polarization by regulating the mir-1-3p\/stat6 axis to promote gastric cancer progression","volume":"23","author":"Deng","year":"2024","journal-title":"Mol Cancer"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2023.216410","article-title":"Gastric Cancer Derived Exosomal Thbs1 Enhanced V\u03b39v\u03b42 t-Cell Function through Activating Rig-I-Like Receptor Signaling Pathway in a N6-Methyladenosine Methylation Dependent Manner","volume":"576","author":"Li","year":"2023","journal-title":"Cancer Lett"},{"key":"B69","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13046-025-03288-9","article-title":"Gc-derived exosomal circman1a2 promotes cancer progression and suppresses T-cell antitumour immunity by inhibiting fbxw11-mediated sfpq degradation","volume":"44","author":"Shen","year":"2025","journal-title":"J Exp Clin Cancer Res"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-21-4383","article-title":"Spatial metabolomics identifies distinct tumor-specific subtypes in gastric cancer patients","volume":"28","author":"Wang","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B71","doi-asserted-by":"publisher","first-page":"2692","DOI":"10.1038\/s41467-023-38360-5","article-title":"Spatially resolved multi-omics highlights cell-specific metabolic remodeling and interactions in gastric cancer","volume":"14","author":"Sun","year":"2023","journal-title":"Nat Commun"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(25)00052-2","article-title":"Gastric cancer","volume":"405","author":"Sundar","year":"2025","journal-title":"Lancet"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(18)32557-1","article-title":"Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectab le gastric or gastro-oesophageal junction adenocarcinoma (Flot4): A randomised, phase 2\/3 trial","volume":"393","author":"Al-Batran","year":"2019","journal-title":"Lancet"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(11)61873-4","article-title":"Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (Classic): A phase 3 open-label, randomised controlled trial","volume":"379","author":"Bang","year":"2012","journal-title":"Lancet"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(18)30132-3","article-title":"Chemotherapy Versus Chemoradiotherapy after Surgery and Preoperative Chemotherapy for Resectab le Gastric Cancer (Critics): An International, Open-Label, Randomised Phase 3 Trial","volume":"19","author":"Cats","year":"2018","journal-title":"Lancet Oncol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.11.017","article-title":"A randomized phase iii trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the artist 2 trial(\u2729)","volume":"32","author":"Park","year":"2021","journal-title":"Ann Oncol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2405195","article-title":"Preoperative chemoradiotherapy for resecta ble gastric cancer","volume":"391","author":"Leong","year":"2024","journal-title":"N Engl J Med"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.4_suppl.327","article-title":"Intraperitoneal and intravenous paclitaxel plus S-1 versus intravenous paclitaxel plus S-1 in gastric cancer patients with peritoneal metastasis: results from the multicenter, randomized, phase 3 dragon-01 trial","volume":"43","author":"Yan","year":"2025","journal-title":". J Clin Oncol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-0413-z","article-title":"Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors","volume":"17","author":"Galluzzi","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/s0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (Checkmate 649): A randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.01601","article-title":"First-line nivolumab plus chemotherapy for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 3-year follow-up of the phase iii checkmate 649 trial","volume":"42","author":"Janjigian","year":"2024","journal-title":"J Clin Oncol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.19918","article-title":"Sintilimab plus chemotherapy for unresecta ble gastric or gastroesophageal junction cancer: the orient-16 randomized clinical trial","volume":"330","author":"Xu","year":"2023","journal-title":"Jama"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02721-w","article-title":"Perioperative toripalimab and chemotherapy in locally advanced gastric or gastro-esophageal junction cancer: A randomized phase 2 trial","volume":"30","author":"Yuan","year":"2024","journal-title":"Nat Med"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02465-7","article-title":"Zolbetuximab plus capox in cldn18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 glow trial","volume":"29","author":"Shah","year":"2023","journal-title":"Nat Med"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00874-2","article-title":"Claudin 18.2 as a novel therapeutic target","volume":"21","author":"Nakayama","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.4036","article-title":"Final overall survival results from phase 3 spotlight study evaluating zolbetuximab + Mfolfox6 as first-line (1l) treatment for patients (Pts) with claudin 18 isoform 2 (Cldn18.2)+, her2\u2013, locally advanced (La) unresecta ble or metastatic gastric or gastroesophageal junction (Mg\/gej) adenocarcinoma","volume":"42","author":"Shitara","year":"2024","journal-title":"J Clin Oncol"},{"key":"B87","doi-asserted-by":"publisher","first-page":"e001014","DOI":"10.1136\/jitc-2020-001014","article-title":"Lag-3: from molecular functions to clinical applications","volume":"8","author":"Maruhashi","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2023.41.16_suppl.2576","article-title":"Efficacy and safety of ibi110 in combination with sintilimab in first-line advanced her2-negative gastric cancer or gastroesophageal junction cancer: updated results from a phase ib study","volume":"41","author":"Mao","year":"2023","journal-title":"J Clin Oncol"},{"key":"B89","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1016\/j.ccell.2024.08.007","article-title":"Combination anti-pd-1 and anti-ctla-4 therapy generates waves of clonal responses that include progenitor-exhausted cd8(+) T cells","volume":"42","author":"Wang","year":"2024","journal-title":"Cancer Cell"},{"key":"B90","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1038\/s41591-024-03450-4","article-title":"First-line cadonilimab plus chemotherapy in her2-negative advanced gastric or gastroesophageal junction adenocarcinoma: A randomized, double-blind, phase 3 trial","volume":"31","author":"Shen","year":"2025","journal-title":"Nat Med"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-024-00870-6","article-title":"Tigit and pd-L1 co-blockade promotes clonal expansion of multipotent, non-exhausted antitumor T cells by facilitating co-stimulation","volume":"5","author":"Nutsch","year":"2024","journal-title":"Nat Cancer"},{"key":"B92","doi-asserted-by":"publisher","first-page":"S1455","DOI":"10.1016\/j.annonc.2024.10.156","article-title":"130mo edge-gastric arm A1: phase ii study of domvanalimab (D), zimberelimab (Z), and folfox in first-line (1l) advanced gastroesophageal (Ge) cancer","volume":"35","author":"Rha","year":"2024","journal-title":"Ann Oncol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1200\/jco.24.00055","article-title":"Integrate iia phase iii study: regorafenib for refractory advanced gastric cancer","volume":"43","author":"Pavlakis","year":"2025","journal-title":"J Clin Oncol"},{"key":"B94","doi-asserted-by":"publisher","first-page":"eabj7002","DOI":"10.1126\/sciadv.abj7002","article-title":"Exosome-mediated genetic reprogramming of tumor-associated macrophages by exoaso-stat6 leads to potent monotherapy antitumor activity","volume":"8","author":"Kamerkar","year":"2022","journal-title":"Sci Adv"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202217089","article-title":"In situ reprogramming of tumor-associated macrophages with internally and externally engineered exosomes","volume":"62","author":"Zhang","year":"2023","journal-title":"Angew Chem Int Ed Engl"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.3_suppl.368","article-title":"Phase ii study of gen-001 in combination with avelumab in patients with pd-L1\u2013positive locally advanced, or metastatic gastric cancer (Gc) or gastroesophageal junction cancer (Gejc) who have progressed after second-line (2l) and beyond (Gen001\u2013201 study)","volume":"42","author":"Lee","year":"2024","journal-title":"J Clin Oncol"},{"key":"B97","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41698-022-00279-3","article-title":"Durable complete response to neoantigen-loaded dendritic-cell vaccine following anti-pd-1 therapy in metastatic gastric cancer","volume":"6","author":"Guo","year":"2022","journal-title":"NPJ Precis Oncol"},{"key":"B98","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.cell.2024.12.010","article-title":"Hyperacute rejection-engineered oncolytic virus for interventional clinical trial in refractory cancer patients","volume":"188","author":"Zhong","year":"2025","journal-title":"Cell"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.3_suppl.317","article-title":"A phase ib\/ii study of askb589 (Anti-claudin 18.2 [Cldn18.2] monoclonal antibody) combined with capox and pd-1 inhibitor as first-line treatment for locally advanced, relapsed and metastatic gastric\/gastro-esophageal junction (G\/gej) adenocarcinoma","volume":"42","author":"Peng","year":"2024","journal-title":"J Clin Oncol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.4_suppl.454","article-title":"Updated efficacy results of askb589 combined with capox and pd-1 inhibitor as first-line treatment for metastatic gastric\/gastro-esophageal junction (G\/gej) adenocarcinoma from a phase ib\/ii study","volume":"43","author":"Peng","year":"2025","journal-title":"J Clin Oncol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.52830","article-title":"Ramucirumab, avelumab, and paclitaxel as second-line treatment in esophagogastric adenocarcinoma: the phase 2 rap (Aio-sto-0218) nonrandomized controlled trial","volume":"7","author":"Thuss-Patience","year":"2024","journal-title":"JAMA Netw Open"},{"key":"B102","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s13045-023-01492-8","article-title":"Challenges and new technologies in adoptive cell therapy","volume":"16","author":"Zhang","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01800-8","article-title":"Claudin18.2-specific car T cells in gastrointestinal cancers: phase 1 trial interim results","volume":"28","author":"Qi","year":"2022","journal-title":"Nat Med"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03037-z","article-title":"Claudin18.2-specific car T cells in gastrointestinal cancers: phase 1 trial final results","volume":"30","author":"Qi","year":"2024","journal-title":"Nat Med"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.4037","article-title":"Effect of autologous lymphocytes combined with chemotherapy as the first-line treatment of advanced gastric cancer","volume":"41","author":"Ma","year":"2023","journal-title":"J Clin Oncol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS2080","article-title":"A phase I\/iia, open-label, multicenter, non-randomized clinical trial to assess the safety and efficacy of cynk-001 in combination with recombinant human interleukin 2 in adults with recurrent resection eligible idh1 wild-type glioblastoma (Gbm)","volume":"40","author":"Bota","year":"","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1623588\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T05:34:33Z","timestamp":1756964073000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1623588\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,4]]},"references-count":106,"alternative-id":["10.3389\/fimmu.2025.1623588"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1623588","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,4]]},"article-number":"1623588"}}